Skip to main content

Advertisement

Table 4 Clinical studies in Lung Cancer

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Patients Trial, ID Follow-up Outcomes Reference
Advanced NSCLC Phase 1b NCT02000947 24 weeks ORR, 23% Grade 3-4 AEs, 35% Antonia et al 2016
Treatment relapsed advanced SCLC Phase 1/2 NCT01928394 ≥ 12 weeks ORR, 23% Median OS, 7.7 months 1-year OS rate, 43% Median PFS, 2.6 months 1-year PFS rate, 19% Grade 3-4 AEs, 30% Antonia et al 2016
Untreated advanced NSCLC Phase 1 NCT01454102 > 9 months ORR, 47% Median PFS, 8.1 months 24-week PFS rate, 68% Grade 3-4 AEs, 37% Hellman et al 2017
Untreated advanced NSCLC Phase 2 NCT02659059 ≥ 6 months In patients with TMB≥10 mutations/megabase ORR, 44% Median PFS, 7.1 months 6-month PFS rate, 55% Grade 3-4 AEs, 29% (all patients) Ready et al 2019
Untreated advanced NSCLC Phase 3 NCT02477826 > 11 months In patients with TMB≥10 mutations/megabase ORR, 45% Median PFS, 7.2 months 12-month PFS rate, 43% HR for disease progression or death, 0.58 Grade 3-4 AEs, 31% Hellman et al 2018